Research
Awards Grant
A Phase 1, Open-Label, Dose-escalation trial of CD33xCD3 Bispecific Antibody in Pediatric patients with Relapsed of Refractory Acute Myeloid Leukemia - COG ADVL 2111
AALL1621- A Phase 2 Study of Inotuzumab Ozogamicin in Children and Young Adults with Relapsed or Refractory CD22+ B-Acute Lymphoblastic Leukemia (B-ALL)
AAML1831A Phase 3 Randomized Trial for Patients with de novo AML Comparing Standard Therapy Including Gemtuzumab (GO) to CPX-351 with GO, and the Addition of the FLT3 Inhibitor Gilteritinib for Patients with FLT3 Mutations”
ANBL1531-JDI- A Phase III Study of 131I Metaiodobenzylguanidine (131I-MIBG) or Crizotinib Added to Intensive Therapy for Children With Newly Diagnosed High-Risk Neuroblastoma (NBL),”
APEC1621I -NCI-COG Pediatric MATCH (Molecular Analysis for Therapy Choice) - Phase 2 subprotocol of Palbociclib in Patients with Tumors Harboring Activating Alterations in Cell Cycle Genes
ARST1921, A Safety, Pharmacokinetic and Efficacy Study of a ?-Secretase Inhibitor, Nirogacestat(PF 03084014; IND# 146375), in Children and Adolescents with Progressive, Surgically Unresectable Desmoid Tumors -AR10441
An Open-Label, Multi-Center Phase 1/2 study of Surufatinib in Combination with Gemcitabine in Pediatric Patients with Recurrent or Refractory Solid Tumors COG ADVL2121
COG Nursing Committee
COG Scientific Council
COG Scientific Council
Cancer Care Delivery Study Chair
Children's Oncology Group NCTN Network Group Operations
Children's Oncology Group NCTN Network Group Operations
Children's Oncology Group NCTN Network Group Operations
Improving the Reach and Effectiveness of STD Prevention, Screening, and Treatment Services in Local Public Health Systems
Larotrectinib for Previously Untreated NTRK-fusion Positive Pediatric Solid Tumors and NTRK-fusion Positive Relapsed Pediatric Acute Leukemias, COG ID ADVL1823
Long-term Follow-up Center to Facilitate Survivorship Research within COG
NIH National Clinical Trials Network (NCTN) Grant (2U10CA180886) Successor to NIH National Clinical Trials Network (NCTN Grant (U10CA180886)
PEPN2111- A Phase 1/2 Trial of CBL0137 (NSC# 825802, IND# 155843) in Patients with Relapsed or Refractory Solid Tumors including CNS Tumors and Lymphoma,
PER CASE REIMBURSEMENT NCORP Operations Grant 7UG1CA189955 -PHI/COG
Per Case Reimbursement (PCR)- NIH National Clinical Trails Network (NCTN) Grant (U10CA180886) -PHI/COG
Per Case Reimbursement - NIH Pediatric Early Phase Clinical Trials Network Grant (7UM1CA228823-04) - PHI/COG
Workload Intensity NIH Nationl Clinical Trials Network (NCTN) Grant (U10DA180886) - PHI/COG
Workload Intensity NIH Pediatric Early Phase Clinical Trials Network Grant (7UM1CA228823-04) -PHI/COG
